• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Non-sustained Ventricular Tachycardia and Hypertrophic Cardiomyopathy: When to Consider it as a Risk Factor for Sudden Death and Total Mortality?

作者信息

Faganello Lucas Simonetto, Pimentel Mauricio

机构信息

Hospital de Clinicas de Porto Alegre, Porto Alegre, RS - Brasil.

出版信息

Arq Bras Cardiol. 2025 Jun 16;122(5):e20250233. doi: 10.36660/abc.20250233. eCollection 2025.

DOI:10.36660/abc.20250233
PMID:40608591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12212382/
Abstract
摘要

相似文献

1
Non-sustained Ventricular Tachycardia and Hypertrophic Cardiomyopathy: When to Consider it as a Risk Factor for Sudden Death and Total Mortality?非持续性室性心动过速与肥厚型心肌病：何时应将其视为猝死和总死亡率的危险因素？
Arq Bras Cardiol. 2025 Jun 16;122(5):e20250233. doi: 10.36660/abc.20250233. eCollection 2025.
2
Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis.儿童肥厚型心肌病性心原性猝死的危险因素：系统评价和荟萃分析。
Eur J Prev Cardiol. 2017 Jul;24(11):1220-1230. doi: 10.1177/2047487317702519. Epub 2017 May 9.
3
Catecholaminergic Polymorphic Ventricular Tachycardia儿茶酚胺能多形性室性心动过速
4
Comparison of Demographic, Clinical, Biochemical, and Imaging Findings in Hypertrophic Cardiomyopathy Prognosis: A Network Meta-Analysis.肥厚型心肌病预后的人口统计学、临床、生化和影像学表现比较：一项网状Meta分析
JACC Heart Fail. 2023 Jan;11(1):30-41. doi: 10.1016/j.jchf.2022.08.022. Epub 2022 Dec 7.
5
Prevalence, risk factors, and outcomes of QT prolongation in primary and RASopathy-associated hypertrophic cardiomyopathy.原发性及RAS病相关肥厚型心肌病中QT间期延长的患病率、危险因素及结局
Heart Rhythm. 2025 Jun 3. doi: 10.1016/j.hrthm.2025.05.059.
6
Laser therapy for treating hypertrophic and keloid scars.激光疗法治疗增生性瘢痕和瘢痕疙瘩。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD011642. doi: 10.1002/14651858.CD011642.pub2.
7
Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.用于室性心动过速的导管消融或抗心律失常药物
N Engl J Med. 2025 Feb 20;392(8):737-747. doi: 10.1056/NEJMoa2409501. Epub 2024 Nov 16.
8
Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers.肥厚型心肌病患者心源性猝死的风险分层：临床风险标志物的系统评价。
Europace. 2010 Mar;12(3):313-21. doi: 10.1093/europace/eup431. Epub 2010 Jan 29.
9
Sudden cardiac death in childhood RASopathy-associated hypertrophic cardiomyopathy: Validation of the HCM risk-kids model and predictors of events.儿童 RAS 相关肥厚型心肌病中的心源性猝死：HCM 风险儿童模型的验证和事件预测因子。
Int J Cardiol. 2023 Dec 15;393:131405. doi: 10.1016/j.ijcard.2023.131405. Epub 2023 Sep 28.
10
Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.肥厚型心肌病中的植入式心脏复律除颤器
Rev Port Cardiol. 2005 Mar;24(3):407-15.

本文引用的文献

1
Prognostic Value of Nonsustained Ventricular Tachycardia in Hypertrophic Cardiomyopathy in a Brazilian Cohort: Comparison with World Literature.非持续性室性心动过速在巴西肥厚型心肌病队列中的预后价值：与世界文献的比较
Arq Bras Cardiol. 2025 Apr;122(5):e20240399. doi: 10.36660/abc.20240399.
2
Validation of ACC/AHA and ESC Sudden Cardiac Death Risk Guidelines in Diverse Hypertrophic Cardiomyopathy Cohort: Stratification HCM Study.ACC/AHA和ESC心脏性猝死风险指南在不同肥厚型心肌病队列中的验证：分层肥厚型心肌病研究
Glob Heart. 2024 Dec 17;19(1):94. doi: 10.5334/gh.1380. eCollection 2024.
3
Low Agreement Among Guidelines for Primary Prevention Implantable Cardioverter-Defibrillator Recommendations in Hypertrophic Cardiomyopathy.肥厚型心肌病原发性预防植入式心律转复除颤器建议指南之间的低一致性。
Am J Cardiol. 2025 Feb 1;236:86-91. doi: 10.1016/j.amjcard.2024.11.007. Epub 2024 Nov 17.
4
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024.肥厚型心肌病诊断与治疗指南 - 2024
Arq Bras Cardiol. 2024 Jul 26;121(7):e202400415. doi: 10.36660/abc.20240415.
5
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.2024 AHA/ACC/AMSSM/HRS/PACES/SCMR 肥厚型心肌病管理指南：美国心脏协会/美国心脏病学会联合临床实践指南委员会的报告。
Circulation. 2024 Jun 4;149(23):e1239-e1311. doi: 10.1161/CIR.0000000000001250. Epub 2024 May 8.
6
Current perspectives of sudden cardiac death management in hypertrophic cardiomyopathy.肥厚型心肌病心脏性猝死管理的当前观点
Heart Fail Rev. 2024 Mar;29(2):395-404. doi: 10.1007/s10741-023-10355-w. Epub 2023 Oct 22.
7
2023 ESC Guidelines for the management of cardiomyopathies.2023年欧洲心脏病学会心肌病管理指南。
Eur Heart J. 2023 Oct 1;44(37):3503-3626. doi: 10.1093/eurheartj/ehad194.
8
Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review.肥厚型心肌病的管理：美国心脏病学会的最新综述。
J Am Coll Cardiol. 2022 Feb 1;79(4):390-414. doi: 10.1016/j.jacc.2021.11.021.
9
Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy.肥厚型心肌病高危患者非持续性室性心动过速的预后意义
Circ Arrhythm Electrophysiol. 2017 Mar;10(3). doi: 10.1161/CIRCEP.116.004604.
10
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy.肥厚型心肌病患者报告生存率的历史趋势。
Heart. 2006 Jun;92(6):785-91. doi: 10.1136/hrt.2005.068577. Epub 2005 Oct 10.